Marijuana smoking is not associated with the promotion of liver disease in subjects coinfected with both hepatitis C and the human immunodeficiency virus (HIV), according to data published online in the journal Clinical Infectious Diseases. Researchers concluded: “[I]n this first prospective evaluation of liver disease progression among HIV-HCV infected persons, we could not demonstrate any important effect of marijuana on liver disease outcomes. A causal association is unlikely: hazard ratios were weak and … there was no dose-response relationship. It is likely that previous studies have been biased by reverse causality as patients use more marijuana to relieve symptoms as liver disease progresses.”
The administration of synthetic cannabinoid agonists limits HIV infection in macrophages (white blood cells that aid in the body’s immune response), according to preclinical data published in the Journal of Leukocyte Biology. Investigators at Temple University School of Medicine in Philadelphia assessed the impact of three commercially available synthetic THC agonists on HIV-infected macrophage cells. Following administration, researchers sampled the cells periodically to measure the activity of an enzyme called reverse transcriptase (RT), which is essential for HIV replication. By day 7, investigators reported that the administration of all three compounds was associated with a significant decreased in HIV replication.
For the second time in recent months, a scientific paper published in a peer-reviewed journal has thoroughly rebutted the present Schedule I status of cannabis under US federal law, which states that the plant and its organic constituents possess a “high potential for abuse,” and that they lack “accepted medical use” and “accepted safety … under medical supervision.” According to a just published review in the German scientific journal Deutsches Ärzteblatt International, scientific findings from over 100 controlled clinical trials involving either cannabis or its constituents provide “clear evidence that […]
The long-term administration of delta-9-THC, the primary psychoactive compound in marijuana, is associated with decreased mortality in monkeys infected with the simian immunodeficiency virus (SIV), a primate model of HIV (human immunodeficiency virus) disease, according to in vivo experimental trial data published in the June issue of the journal AIDS Research and Human Retroviruses.
Investigators at […]
NORML has recently posted online the fourth edition of its popular and comprehensive booklet, “Emerging Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature.”
Updated and revised for 2011, this report reviews approximately 200 newly published scientific studies assessing the safety and efficacy of marijuana and its compounds in the treatment […]